Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5188766
Max Phase: Preclinical
Molecular Formula: C38H52N10O12S2
Molecular Weight: 905.03
Associated Items:
ID: ALA5188766
Max Phase: Preclinical
Molecular Formula: C38H52N10O12S2
Molecular Weight: 905.03
Associated Items:
Canonical SMILES: CS[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4ccccc34)SC[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N2
Standard InChI: InChI=1S/C38H52N10O12S2/c1-16(26(51)14-49)30-36(59)43-22-9-20-19-6-4-5-7-21(19)45-37(20)62-15-24(42-28(53)11-41-35(58)31(17(2)61-3)46-29(54)12-40-32(22)55)33(56)44-23(10-27(39)52)38(60)48-13-18(50)8-25(48)34(57)47-30/h4-7,16-18,22-26,30-31,45,49-51H,8-15H2,1-3H3,(H2,39,52)(H,40,55)(H,41,58)(H,42,53)(H,43,59)(H,44,56)(H,46,54)(H,47,57)/t16-,17+,18+,22-,23-,24-,25-,26-,30-,31-/m0/s1
Standard InChI Key: ADDIRMXZWPXDLC-NODGECNSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 905.03 | Molecular Weight (Monoisotopic): 904.3208 | AlogP: -4.94 | #Rotatable Bonds: 7 |
Polar Surface Area: 343.58 | Molecular Species: NEUTRAL | HBA: 14 | HBD: 12 |
#RO5 Violations: 3 | HBA (Lipinski): 22 | HBD (Lipinski): 13 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 10.08 | CX Basic pKa: | CX LogP: -6.38 | CX LogD: -6.38 |
Aromatic Rings: 2 | Heavy Atoms: 62 | QED Weighted: 0.12 | Np Likeness Score: 0.91 |
1. Todorovic M, Rivollier P, Wong AAWL, Wang Z, Pryyma A, Nguyen TT, Newell KC, Froelich J, Perrin DM.. (2022) Rationally Designed Amanitins Achieve Enhanced Cytotoxicity., 65 (15.0): [PMID:35696491] [10.1021/acs.jmedchem.1c02226] |
Source(1):